Reduced activity of the hypertension-associated Lys528Arg mutant of human adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase-1  by Goto, Yoshikuni et al.
FEBS Letters 580 (2006) 1833–1838Reduced activity of the hypertension-associated Lys528Arg mutant
of human adipocyte-derived leucine aminopeptidase
(A-LAP)/ER-aminopeptidase-1
Yoshikuni Gotoa,b, Akira Hattoria, Yasuhiro Ishiib, Masafumi Tsujimotoa,*
a Laboratory of Cellular Biochemistry, RIKEN, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan
b Laboratory of Applied Protein Chemistry, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-0054, Japan
Received 15 December 2005; revised 21 January 2006; accepted 15 February 2006
Available online 24 February 2006
Edited by Irmgard SinningAbstract The adipocyte-derived leucine aminopeptidase (A-
LAP)/ER aminopeptidase-1 is a multi-functional enzyme belong-
ing to the M1 family of aminopeptidases. It was reported that the
polymorphism Lys528Arg in the human A-LAP gene is associ-
ated with essential hypertension. In this study, the role of
Lys528 in the enzymatic activity of human A-LAP was exam-
ined by site-directed mutagenesis. Among non-synonymous poly-
morphisms tested, only Lys528Arg reduced enzymatic activity.
The replacement of Lys528 with various amino acids including
Ala, Met, His and Arg caused a signiﬁcant decrease in the enzy-
matic activity. Molecular modeling of the enzyme suggested that
Lys528 is located near the entrance of the substrate pocket.
These results suggest that Lys528 is important for maximal
activity of A-LAP by maintaining the appropriate structure of
the substrate pocket of the enzyme. The reduced enzymatic activ-
ity of A-LAP may cause high blood pressure and the observed
association between the polymorphism and hypertension.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Aminopeptidases hydrolyze the N-terminal amino acids of
proteins or peptide substrates. They are distributed widely in
animal and plant tissues as well as in bacteria and fungi, sug-
gesting that they play important roles in various biological
processes [1]. Previously, we cloned a cDNA for placental leu-
cine aminopeptidase (P-LAP)/oxytocinase, a type II mem-
brane-spanning protein with a relatively long N-terminal
cytosolic domain [2]. Subsequently, we cloned cDNAs encod-
ing adipocyte-derived leucine aminopeptidase (A-LAP) and
leukocyte-derived arginine aminopeptidase (L-RAP) byAbbreviations: A-LAP, adipocyte-derived leucine aminopeptidase;
LTA4H, leukotriene A4 hydrolase; NA, b-naphtylamide; L-RAP, le-
ukocyte-derived arginine aminopeptidase; P-LAP, placental leucine
aminopeptidase; TIFF3, Tricorn-interacting factor F3
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indicated that P-LAP, A-LAP and L-RAP are most closely re-
lated among the M1 family of aminopeptidases, which contain
GAMEN and HEXXH(X)18E consensus motifs. Therefore we
proposed that they should be classiﬁed into ‘‘the oxytocinase
subfamily of M1 aminopeptidases’’ [5].
A-LAP is a multi-functional aminopeptidase shown to play
roles in the regulation of blood pressure, angiogenesis and
antigen presentation to MHC class I molecules [5–9]. More-
over, this enzyme was shown to bind to cytokine receptors
such as TNF type I receptor, interleukin (IL)-6 a-receptor,
and IL-1 type II receptor, and promote ectodomain shedding
of these receptors [10–12]. A-LAP is also designated puromy-
cin-insensitive leucine-speciﬁc aminopeptidase (PILS-AP)
[13], ER-aminopeptidase associated with antigen presentation
(ERAAP) [8], ER-aminopeptidase (ERAP)-1 [9] and amino-
peptidase regulator of TNFR1 shedding (ARTS-1) [10] due
to its multi-functional properties.
Since A-LAP cleaves and inactivates angiotensin II and con-
verts kallidin to bradykinin eﬃciently, it was suggested that the
enzyme plays a role in the regulation of blood pressure [14]. By
screening for polymorphisms in the human A-LAP gene,
Yamamoto et al. identiﬁed the association of Lys528Arg with
essential hypertension and hypothesized that mutant A-LAP
with Lys528Arg is less active than the wild-type enzyme [6].
It was also reported that this polymorphism determines the de-
gree of regression of left ventricular hypertrophy during anti-
hypertensive treatment in patients with essential hypertension
and left ventricular hypertrophy [15]. These results suggest that
Lys528 of wild-type A-LAP plays a role in the enzymatic ac-
tion of the enzyme.
In the current study, we have examined the importance of
this residue in the enzymatic action of A-LAP by mutational
analysis. Our data indicate that Lys528 is indeed important
for the maximal activity of A-LAP by maintaining high
aﬃnity-binding of the substrate to the enzyme.2. Materials and methods
2.1. Site-directed mutagenesis
The cDNAs encoding formutantA-LAPswere generated by two-step
PCR. PCRs were carried out in 0.2 ml tubes with a 30-ll reaction vol-
ume. The sequences of sense oligonucleotide primers used to introduce
point mutations in A-LAP cDNA, are listed in Table 1. First PCRswere
carried out for 1 cycle at 98 C for 3.5 min, followed by 10 cycles at 95 C
for 0.5 min, at 55 C for 1 min, and at 72 C for 2 min using Pyrobestblished by Elsevier B.V. All rights reserved.
Table 1











The underlined bases encode a new amino acid.
aPrimer sequences for the sense strand are shown.
1834 Y. Goto et al. / FEBS Letters 580 (2006) 1833–1838DNA polymerase (Takara, Kyoto Japan). Sense primer A (5 0-CAC-
CAACCCTAAAAAACCGCCACCATGGTGTTTCTGCCC-3 0) con-
taining a CACC sequence for directional cloning and initiation ATG
codon and antisense primers complimentary to the sequences listed in
Table 1 were employed for the ampliﬁcation of upper stream fragments.
Down stream fragments with the sequence for 6 ·His tag at the 3 0-end
were ampliﬁed using mutagenic sense primers and primer B (5 0-GAC-
TGTCGACTTAGTGATGGTGATGGTGATGCATACGTTCAAG-
CTT-3 0).
The two products of ﬁrst PCR were used as templates for the second
PCR. Second PCRs were carried out with primers A and B for 1 cycle
at 98 C for 3.5 min, followed by 25 cycles at 95 C for 0.5 min, at
55 C for 1 min, and at 72 C for 2 min. The resultant products were
inserted into the entry vector, pENTR-D-TOPO, using a TOPO-clon-
ing system (Invitrogen). The sequences of the products were conﬁrmed
by automated sequencing on an Applied Biosystems model 377.
2.2. Expression and puriﬁcation of recombinant wild-type and mutant
A-LAPs in the baculovirus system
Human wild-type and mutant A-LAPs with C-terminal His tags in-
serted into pENTR-D-TOPO were transfected to the destination vec-
tor pDEST8 via a LR reaction (Invitrogen). The pDEST8 vectors
containing A-LAP cDNAs were transformed to competent DH10bac
Escherichia coli cells harboring the baculovirus genome (bacmid) and
a transposition helper vector (Invitrogen). Subsequently, insect Sf9
cells were transfected with recombinant bacmids using the Cellfectin
reagent (Invitrogen). After a 3-day incubation period, recombinant
baculoviruses were isolated and used to infect Sf9 cells at a multiplicity
of infection of 0.1. Three days after infection, the ampliﬁed viruses
were harvested.
For the production of A-LAPs, Sf9 cells were grown at 27 C in
100 ml of Sf-900II medium (Gibco) and 1.5 · 106 cells/ml were infected
at a multiplicity of infection of 1–3. After 3 days, the culture medium
was collected after centrifugation at 5000 · g for 15 min.
The culture medium was loaded onto a hydroxyapatite (Toyobo,
Osaka, Japan) column (bed volume: 10 ml) pre-equilibrated with
5 mM phosphate buﬀer (pH 7.5). After extensive washing with the
same buﬀer, A-LAP was eluted from the column with 100 mM phos-
phate buﬀer (pH 7.5). The eluate was then loaded onto a Co2+-chelat-
ing Sepharose (Pharmacia) column (bed volume: 1 ml) pre-equilibrated
with 10 mM phosphate buﬀer (pH 7.5) containing 0.1 M NaCl. After
extensive washing with 10 mM phosphate buﬀer (pH 7.5) containing
0.1 M NaCl and 5 mM imidazole, A-LAP was eluted with 10 mM
phosphate buﬀer (pH 7.5) containing 0.1 M NaCl and 100 mM imidaz-
ole. The A-LAP-containing fractions were extensively dialyzed against
25 mM Tris–HCl buﬀer (pH 7.5) containing 0.125 M NaCl and con-
centrated with a ultraﬁltration membrane and stored at 20 C prior
to use.
2.3. Measurement of aminopeptidase activity
A-LAP activity was determined with a synthetic ﬂuorogenic sub-
strate, L-leucyl-b-naphtylamide (Leu-NA) (Bachem, Bubendorf, Swit-
zerland). The reaction mixture containing various concentrations of
Leu-NA and either wild-type or mutant A-LAPs (100 ng/ml) in
500 ll of 20 mM phosphate buﬀer (pH 7.5) containing 10 lg/ml bovine
serum albumin (BSA) was incubated at 37 C for 5 min. After the incu-bation, the amount of b-naphtylamine released was measured by spec-
troﬂuorophotometry (F-2000, Hitachi) at an excitation wavelength of
335 nm and an emission wavelength at 410 nm. The kinetic parameters
(Km and Vmax) were calculated from Lineweaver–Burk plots. The re-
sults were represented by Km, relative kcat and relative kcat/Km values.
All measurements were performed in triplicate.
2.4. Cleavage of peptide hormones by recombinant A-LAPs
Peptide hormones (Peptide Institute, Osaka, Japan) (25 lM) were
incubated with either wild-type or mutant A-LAPs (2 lg/ml) at 37 C
in 20 mM phosphate buﬀer (pH 7.5) containing 10 lg/ml BSA. The
reaction was terminated by addition of 2.5% (v/v) formic acid. The
peptides generated were separated by reverse-phase HPLC on a COS-
MOSIL (4.6 · 250 mm) column (Nacalai Tesque, Kyoto, Japan) using
a Gilson HPLC system with a Hewlett-Packard HP 1040A diode-array
detector. Peptides generated from angiotensin II or kallidin were eluted
isocratically with 20% acetonitrile in 0.09% triﬂuoroacetic acid at a
ﬂow rate of 0.5 ml/min. The molecular masses of peptides were deter-
mined by matrix-assisted laser desorption ionization time of ﬂight
(MALDI-TOF) MS with a REFLEX mass spectrometer (Bruker-
Franzen Analytik) using 2-mercaptobenzothiazole as the matrix.
2.5. Molecular modeling of human A-LAP
The recently published X-ray crystallographic structures of human
leukotriene A4 hydrolase (LTA4H) [16] and Thermoplasma acidophi-
lum Tricorn-interacting factor F3 (TIFF3) [17] were used as templates
for modeling the substrate pocket of human A-LAP using SWISS-
MODEL Internet server (http://www.expasy.org/swissmod/). The
structure was displayed using the CueMol program (Ishitani, R.,
CueMol: Molecular Visualization Framwork, http://cuemol.source-
forge.jp).
2.6. Materials
Aminopeptidase inhibitors (amastatin, bestatin and oxidized leuci-
nethiol) were purchased from Sigma. Oxidized leucinethiol (Leu-SH)
was reduced by dithiothreitol before use.3. Results and discussion
Until now, there are 33 polymorphisms in the human A-
LAP gene and 10 non-synonymous polymorphisms are re-
ported [6]. Among them, A1533G caused the substitution of
Lys528 to arginine. (Hereafter we refer to the mutant resulting
from this polymorphism as Lys528Arg A-LAP.) It has been re-
ported that Lys528Arg A-LAP is associated with essential
hypertension [6]. We have shown that A-LAP can inactivate
angiotensin II and convert kallidin (Lys-bradykinin) to brady-
kinin in vitro [14]. These results prompted us to examine the
enzymatic properties of the wild-type and mutant enzymes de-
rived from non-synonymous polymorphisms reported in Ref.
[6]. Our initial experiments showed that transcriptional and
translational rates of the non-synonymous polymorphic genes
are rather constant (data not shown). Therefore it is reason-
able to speculate that reduced A-LAP activity may cause
hypertension.
To examine the hypothesis, wild-type and mutant A-LAPs
were transiently expressed in a baculovirus system and puriﬁed
to homogeneity on SDS–PAGE (Fig. 1A). All the enzymes
showed single bands with apparent molecular weights of
110 kDa as expected. We used these preparations to measure
the enzymatic activity of the enzymes thereafter.
Table 2 shows the enzymatic activities of wild-type and mu-
tant A-LAPs using Leu-NA as a substrate. A signiﬁcant reduc-
tion of enzymatic activity (shown by relative kcat/Km) was seen
only in Lys528Arg A-LAP. The other mutant enzymes largely
retained the activity toward this synthetic substrate. Nearly the
Fig. 1. SDS–PAGE of puriﬁed recombinant wild-type and mutant A-
LAPs.
Table 2
Kinetic parameters of wild-type and mutant A-LAPs








Wild-type Major allele 685 ± 38 100 100
Glu56Lys G166A 595 ± 98 113 ± 8 130 ± 13
Pro127Arg C380G 730 ± 170 131 ± 11 123 ± 13
Ile276Met A828G 461 ± 48 84 ± 7 120 ± 10
Lys528Arg A1583G 2040 ± 201 74 ± 8 25 ± 1
Asp575Asn G1723A 959 ± 92 170 ± 6 121 ± 5
Gln730Glu C2188G 723 ± 37 118 ± 5 112 ± 2
Lys528Ala – 2998 ± 402 97 ± 9 22 ± 1
Lys528Met – 2936 ± 115 101 ± 6 23 ± 1
Lys528His – 2976 ± 474 65 ± 6 15 ± 4
aThe values are means ± S.D. (n = 3).
Fig. 2. Enzymatic activity of wild-type and mutant A-LAPs toward
peptide hormones. (A) Cleavage of angiotensin II. Angiotensin II
(25 lM) was incubated with either wild-type or Lys528Arg mutant A-
LAP (2 lg/ml) at 37 C for 60 min. The peptides generated were loaded
onto an HPLC column and separated as described in Section 2. (I:
angiotensin II; II: angiotensin III; III: angiotensin IV; IV: de-[Val]-
angiotensin IV.) (B) Conversion of kallidin to bradykinin. Kallidin
(25 lM) was incubated with either wild-type or Lys528Arg mutant A-
LAP (2 lg/ml) at 37 C for 20 min. The peptides generated were loaded
onto an HPLC column and separated as described in Section 2. (I:
kallidin; II: bradykinin.) (C) Cleavage of angiotensin II and kallidin by
wild-type and mutant A-LAPs. 25 lM of angiotensin II (closed bar)
and kallidin (open bar) were incubated with various A-LAPs (2 lg/ml)
at 37 C for 60 min and 20 min, respectively. The activity of wild-type
A-LAP was taken as 100%.
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Met-NA, was employed (data not shown). These results indi-
cate that among non-synonymous polymorphisms observed
in the A-LAP gene, only Lys528Arg polymorphism causes a
signiﬁcant decrease in the enzymatic activity of the resultant
mutant A-LAP.
Next we compared the hydrolytic activities of various A-
LAPs toward natural hormones (Fig. 2). We chose angiotensin
II and kallidin as substrates in this study because among pep-
tide hormones that can be substrates of A-LAP in vitro, these
two hormones are involved in the regulation of blood pressure
[14]. Fig. 2A shows the cleavage of angiotensin II by the wild-
type and Lys528Arg A-LAPs. Analysis of the degradation
products showed that the wild-type enzyme cleaved the N-ter-
minal Asp residue eﬃciently in our assay system and the gen-
eration of angiotensin III was clearly detected within 1 h. The
appearance of angiotensin IV was also detected through subse-
quent cleavage of the Arg residue. On the other hand, Ly-
s528Arg A-LAP was less active toward the hormone and a
60% decrease in the generation of angiotensin III was ob-
served. No angiotensin IV was detected during the incubation
period. When the conversion of kallidin to bradykinin was
measured, it was found that Lys528Arg A-LAP was also less
active than the wild-type enzyme and a 70% decrease in the
conversion was observed (Fig. 2B). These results suggest that
Lys528Arg A-LAP is less active than wild-type A-LAP toward
natural hormones that can be substrates of the enzyme.Fig. 2C summarizes the hydrolytic activities of the wild-type
and various mutant A-LAPs toward angiotensin II and kalli-
din. As in the case of synthetic substrates, only Lys528Arg
A-LAP showed decreased activity toward the hormones. Other
mutants tested showed little diﬀerence from the wild-type en-
zyme. These results suggest that the association of this poly-
morphism in the A-LAP gene with hypertension was at least
in part due to the reduced enzymatic activity of the mutant
enzyme.
To elucidate the signiﬁcance of Lys528 in the enzymatic
activity of A-LAP, this residue was changed to various amino
acids. All mutants were transiently expressed in a baculovirus
system and puriﬁed to homogeneity (Fig. 1B).
As shown in Table 2, all mutants showed decreased activities
toward Leu-NA when compared with the wild-type enzyme.
These results suggest that Lys528 is required for the maximal
activity of the enzyme. It is notable that all mutants showed
1836 Y. Goto et al. / FEBS Letters 580 (2006) 1833–18382–3-fold increase in Km values, indicating that this residue par-
ticipates in the determination of substrate-binding aﬃnity to
the enzyme.
We then compared the hydrolytic activities of wild-type and
various Lys528-replaced mutant A-LAPs toward angiotensin
II and kallidin (Fig. 3). As shown in the ﬁgure, all mutants
were less active than the wild-type enzyme. Of note, a naturally
occurring Lys528Arg A-LAP was less active than the other
mutants tested. These results support the notion that Lys528
is necessary for maximal activity of the enzyme by maintaining
the aﬃnity for substrates.
We next tried to estimate the role of this residue in the enzy-
matic action by measuring the Ki values of various aminopep-
tidase inhibitors for the wild-type and Lys528Arg A-LAPs. As
shown in Table 3, amastatin and bestatin showed a 2.90- and
5.38-fold increase in the Ki value for Lys528Arg A-LAP,
respectively. In contrast, no diﬀerence was observed when
Leu-SH was used as an inhibitor. We also examined the eﬀects
of inhibitors on the activities of Glu320Gln and His357Phe A-
LAPs. While Glu320 in the GAMEN motif is important for
the interaction with N-terminal a-amino group of peptide sub-
strate, His357 in HEXXH motif is a Zn2+-binding ligand
[18,19]. The inhibitory activities of amastatin and bestatin were
much less to both mutants than those to wild-type and Ly-
s528Arg A-LAPs. Moreover, signiﬁcant increases in the Ki val-
ues of Leu-SH for both mutants (22.5- and 169-fold increase to
Glu320 and His357, respectively) were observed. These resultsFig. 3. Cleavage of angiotensin II and kallidin by the wild-type and
Lys528 mutant A-LAPs. 25 lM of angiotensin II (closed bar) and
kallidin (open bar) were incubated with various A-LAPs (2 lg/ml) at
37 C for 60 min and 20 min, respectively. The activity of wild-type A-
LAP was taken as 100%.
Table 3






Wild-type 20.0 ± 5.0 (1.00) 53.7 ±
Lys528Arg 57.9 ± 8.4 (2.90) 289 ±
Glu320Gln 205 ± 12 (10.3) 526 ±
His357Phe 162 ± 20 (8.10) 507 ±
aThe values are means ± S.D. (n = 3).suggest the diﬀerent role of Lys528 from Glu320 and His357,
both of which are important for the integrity of substrate
pocket structure.
Alignment of the M1 family members indicates that Lys528
is conserved only in the oxytocinase subfamily (Fig. 4A).
Therefore it is possible that the role of this residue in the enzy-
matic activity is common to the subfamily members. Recently,
the crystal structures for LTA4H and TIFF3 were solved
[16,17]. Human LTA4H and T. acidophilum TIFF3 show
11.8% and 22.2% similarity to human A-LAP, respectively.
The sequence similarity of these two proteins to A-LAP al-
lowed us to model the structure of A-LAP using these two en-
zymes as templates (Fig. 4B). Modeling of the substrate pocket
of A-LAP reveals that Lys528 is clustered with other amino
acid residues required for maximal activity (i.e., His417 [20]
and His548 (our unpublished result)) near the entrance of
the pocket. We speculate that interactions between these resi-
dues contribute to the high aﬃnity-binding of substrate to
the enzyme by maintaining the appropriate shape of the sub-
strate pocket of the enzyme. Taken together, it is quite con-
ceivable that Lys528 is important for the formation and
maintenance of the entrance of substrate pocket of the enzyme.
For a detailed analysis of the mode of enzymatic action of A-
LAP, we have to await the determination of the three-dimen-
sional structure of the enzyme by X-ray crystallography.
Since only the crystal structure of LTA4H and TIFF3 have
been resolved among the M1 family of aminopeptidases, essen-
tial amino acid residues for the enzymatic activity of the family
members were identiﬁed by molecular modeling and site-direc-
ted mutagenesis [18–26]. These studies usually identiﬁed con-
served residues among M1 family members. In this study, we
have identiﬁed Lys528 as a residue aﬀecting the enzymatic
activity of A-LAP that was not identiﬁed in the previous stud-
ies. The signiﬁcance of this residue was initially suggested by
an analysis reporting the association of the Lys528Arg poly-
morphism in the A-LAP gene with essential hypertension [6].
Our data provide the molecular bases of the association be-
tween polymorphisms of the A-LAP gene and essential
hypertension in that Lys528Arg A-LAP is less active than
the wild-type enzyme due to a reduction in aﬃnity for sub-
strate hormones. It is plausible that the reduced cleavage of
substrate peptides such as angiotensin II and kallidin may re-
sult in high blood pressure and the observed association be-
tween the polymorphism and hypertension. To further
analyze the pathophysiological signiﬁcance of the polymor-
phism, it would also be interesting to compare the antigen pre-
sentation activities of wild-type and mutant A-LAPs to MHC





0.8 (1.00) 0.15 ± 0.02 (1.00)
40 (5.38) 0.16 ± 0.01 (1.07)
3 (9.80) 3.38 ± 0.43 (22.5)
26 (9.44) 25.4 ± 5.2 (169)
Fig. 4. Molecular modeling of human A-LAP. (A) Alignment of the human A-LAP amino acid sequence with the sequences of other human
aminopeptidases belonging to the M1 family and T. acidophilum TIFF3. APA: aminopeptidase A, APN: aminopeptidase N. (B) Modeling of the
substrate pocket of human A-LAP using human LTA4H and T. acidophilum TIFF3 as templates.
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